Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 833 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Graft Versus Host Disease Clear all
Completed Phase 1 Interventional

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

NCT00005988
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myeloma
Interventions
cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, in vitro-treated bone marrow transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 40 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
2
States / cities
Boston, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 5, 2026, 6:20 PM EDT
Terminated Phase 2 Interventional Results available

Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies

NCT03717480
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
ClinicMACs
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 5, 2026, 6:20 PM EDT
Active, not recruiting Not applicable Interventional

Digital Health Intervention to Promote Quality of Life in Adults With Chronic Graft Versus Host Disease

NCT06688942
View directory record Official record
Conditions
Chronic Graft-Versus-Host Disease, Quality of Life
Interventions
Horizons App Intervention
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Music-based Treatments and Pain: Underlying Mechanisms and the Beneficial Effects of Music-Based Treatments

NCT05578781
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Music Therapy, Music Medicine, Control group
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

NCT00014469
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
busulfan, melphalan, methotrexate, tacrolimus, allogeneic bone marrow transplantation
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus as Treatment of Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease

NCT00388362
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Sirolimus, Prednisone
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2017 · Synced Oct 5, 2026, 6:20 PM EDT
Terminated Not applicable Interventional Results available

Efalizumab in Treating Patients With Graft-Versus-Host Disease of the Skin That Did Not Respond to Previous Steroids

NCT00489216
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
efalizumab
Biological
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 5, 2026, 6:20 PM EDT
Completed No phase listed Observational

Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat

NCT02409134
View directory record Official record
Conditions
Quality of Life, Graft-vs-Host Disease
Interventions
Not listed
Lead sponsor
Sung Choi, M.D.
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 5, 2026, 6:20 PM EDT
Terminated Phase 2 Interventional Results available

A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients

NCT01972438
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
ASEDs, Saline
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 5, 2026, 6:20 PM EDT
Terminated Phase 2 Interventional

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

NCT06271616
View directory record Official record
Conditions
Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Interventions
Echocardiography Test, Ibrutinib
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant

NCT02206035
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplantation
Interventions
Tacrolimus, Methotrexate, Tocilizumab
Drug
Lead sponsor
William R. Drobyski, MD
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 5, 2026, 6:20 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

NCT02619617
View directory record Official record
Conditions
Cluster Headache - Episodic and Chronic
Interventions
SOM230, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Culver City, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 5, 2026, 6:20 PM EDT
No Longer Available No phase listed Expanded access

Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD

NCT00759018
View directory record Official record
Conditions
Graft vs Host Disease, Graft-Versus-Host Disease
Interventions
remestemcel-L
Biological
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
2 Months to 17 Years
U.S. locations
24
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

NCT03339297
View directory record Official record
Conditions
Graft-versus-host Disease, Acute-graft-versus-host Disease
Interventions
Defibrotide, Standard of Care
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
18
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 5, 2026, 6:20 PM EDT
Terminated Phase 2 Interventional Results available

Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)

NCT01757197
View directory record Official record
Conditions
Glucocorticosteroid Refractory Acute GVHD
Interventions
Toclizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 1 Interventional Results available

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

NCT00513474
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
busulfan, cyclophosphamide, cyclosporin-A, etoposide, methotrexate, rasburicase, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation, fludarabine, allopurinol
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 5, 2026, 6:20 PM EDT
Recruiting Phase 1 Interventional

Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies

NCT05443425
View directory record Official record
Conditions
Acute Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm
Interventions
Cholestyramine, Leflunomide, Steroid Therapy
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 5, 2026, 6:20 PM EDT
Terminated Phase 2 Interventional Results available

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

NCT02877082
View directory record Official record
Conditions
Acute Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
Interventions
Thymoglobulin, Bortezomib, Tacrolimus
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

NCT00813124
View directory record Official record
Conditions
Stem Cell Transplantation, Leukemia
Interventions
Fludarabine, Busulfan, Thymoglobulin, Azacitidine, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 5, 2026, 6:20 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury

NCT01910818
View directory record Official record
Conditions
Chronic Radiation Dermatitis
Interventions
Fractional CO2 laser treatment, No treatment
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

NCT00825487
View directory record Official record
Conditions
Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies
Interventions
ARQ 621
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Phoenix, Arizona • Santa Monica, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2011 · Synced Oct 5, 2026, 6:20 PM EDT
Terminated Not applicable Interventional Results available

Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

NCT02338232
View directory record Official record
Conditions
GVHD
Interventions
Telmisartan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 5, 2026, 6:20 PM EDT
Withdrawn Phase 2 Interventional

Tocilizumab for Chronic Graft-versus-Host Disease Treatment

NCT02174263
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
tocilizumab, laboratory biomarker analysis, quality-of-life assessment
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
5
States / cities
Phoenix, Arizona • Rochester, Minnesota • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated May 6, 2016 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Not applicable Interventional Results available

Treatment for Migraines With an Implantable Device

NCT00286078
View directory record Official record
Conditions
Migraine
Interventions
Precision
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
15
States / cities
Denver, Colorado • Stamford, Connecticut • Augusta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 5, 2026, 6:20 PM EDT